Publications by authors named "Inigo Rodriguez-Baz"
Objectives: Atypical variants are rare in genetically determined Alzheimer disease (AD). This case describes a patient with Down syndrome-associated Alzheimer disease (DSAD) who presented with symptoms of posterior cortical atrophy (PCA).
Methods: We conducted a clinical and cognitive evaluation, genotyping, determination of AD biomarkers in CSF, structural MRI, [18F]FDG-PET, and tau-PET ([18F]PI2620) scans.
What Can We Learn About Alzheimer's Disease from People with Down Syndrome?
Curr Top Behav Neurosci
November 2024
Article Synopsis
- Down syndrome (DS) is a common genetic disorder that causes intellectual disability, affecting about 1 in 700 births globally, with significant populations in Europe and the U.S.
- Advances in healthcare have increased the lifespan of those with DS, leading to new challenges related to aging, particularly the risk of Alzheimer's disease (AD).
- The chapter will discuss the importance of studying DS to better understand AD biology and the potential insights that could benefit both individuals with DS and the broader population, while also outlining future research objectives.
Article Synopsis
- This study investigates the occurrence and characteristics of cerebral microbleeds in adults with Down syndrome (DS), a population at risk for Alzheimer's disease (AD), to understand their relationship with clinical variables and cognitive outcomes.
- The research involves a cross-sectional analysis of 276 individuals with DS and 158 healthy controls, using neuroimaging, genetic testing, and cognitive assessments to evaluate microbleed prevalence and its associations with AD biomarkers.
- Results show that individuals with DS are more likely to have microbleeds compared to controls, with prevalence increasing with age and severity of AD, particularly in those carrying the ε4 allele, but not linked to common vascular risk factors.
Article Synopsis
- Recent advances in blood markers for Alzheimer's disease detection show high accuracy, but their practicality in clinical settings remains uncertain due to the need for sensitive equipment.
- A study of 290 participants at a specialized memory clinic revealed that plasma pTau levels were significantly higher in those with amyloid-positive results compared to amyloid-negative individuals, indicating potential for blood tests in diagnosis.
- The automated platform demonstrated a strong capacity to accurately differentiate between amyloid-positive and amyloid-negative patients, with pTau showing the highest accuracy and a low misclassification rate, suggesting it could be a reliable diagnostic tool.
Background: Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown.
Methods: We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio.
Objectives: Alzheimer's disease (AD) is considered the most common cause of dementia in older people. Recently, blood-based markers (BBM) Aβ1-42, Aβ1-40, and phospho Tau181 (p-Tau181) have demonstrated the potential to transform the diagnosis and prognostic assessment of AD. Our aim was to investigate the effect of different storage conditions on the quantification of these BBM and to evaluate the interchangeability of plasma and serum samples.
View Article and Find Full Text PDFIntroduction: Mechanical thrombectomy (MT) has meant a change in natural history of acute ischemic stroke. Our aim is to assess the possible association between different factors and prognosis in patients treated with MT in a third degree Spanish hospital.
Methods: Cross-sectional study including 198 patients underwent MT because of acute ischemic stroke between 2012 and 2020.